Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 250Lung Neoplasms 176Small Cell Lung Carcinoma 37Breast Neoplasms 37Neoplasms 25Neoplasm Metastasis 19Adenocarcinoma of Lung 17Ovarian Neoplasms 14Mesothelioma, Malignant 14Melanoma 13Stomach Neoplasms 12Mesothelioma 12Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Prostatic Neoplasms 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Renal Cell 9Lung Diseases 7Head and Neck Neoplasms 7Colonic Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Thymoma 5Sarcoma 5Pleural Effusion, Malignant 5Carcinoma, Ovarian Epithelial 5Carcinoma 5

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Camurati-Engelmann Syndrome × Thoracic × Clear all
NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡